MedTrace Logo

Decitabine and Midostaurin in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia

NCT01846624 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 13

Last updated 2018-09-27

Study results available
· View outcomes & findings →

Summary

This phase 2 study evaluates the sequential combination of decitabine then midostaurin for the treatment of newly-diagnosed acute myeloid leukemia (AML) in older patients.

Conditions

  • Acute Myeloid Leukemia (AML) With Multilineage Dysplasia Following Myelodysplastic Syndrome, in Adults
  • AML (Adult) With 11q23 (MLL) Abnormalities
  • AML (Adult) With Del (5q)
  • AML (Adult) With Inv (16) (p13; q22)
  • AML (Adult) With t (16;16) (p13; q22)
  • AML (Adult) With t (8; 21) (q22; q22)
  • Secondary AML (Adult)
  • Untreated AML (Adult)

Interventions

DRUG

Decitabine

Given IV

DRUG

Midostaurin

Given PO

Sponsors & Collaborators

  • David Iberri

    lead OTHER

Principal Investigators

  • David J Iberri, MD · Stanford University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-06-30
Primary Completion
2016-07-22
Completion
2016-08-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01846624 on ClinicalTrials.gov